alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['T474I'],"[{'ncitCode': 'C81934', 'drugName': 'Ibrutinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 533, 'code': 'CLLSLL', 'color': 'LimeGreen', 'name': 'Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'mainType': {'id': None, 'name': 'Mature B-Cell Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'MBN', 'level': 5, 'tumorForm': 'LIQUID'}",[],"['27571029', '27626698']",[],"Ibrutinib is an irreversible small-molecule tyrosine kinase inhibitor of BTK that is NCCN-listed and FDA-approved for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with or without 17p deletion. Structural modeling of BTK revealed that T474 is located in the kinase domain at the ibrutinib docking site, suggesting that the T474I mutation can directly attenuate inhibitor binding (PMID: 27626698). In vitro, ibrutinib demonstrated eight-fold lower potency against T474I (IC50 = 5.6 nM) compared to wildtype BTK (PMID: 27571029)."
